Trials / Recruiting
RecruitingNCT06979323
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
The IMAGINE Study: A Phase 3b Open Label, Single Arm Study to Assess the Effect of Depemokimab on Airway Structure and Function in Asthma With Type 2 Inflammation Characterized by an Eosinophilic Phenotype Utilizing Quantitative High-resolution CT and Bronchoscopic Airway Sampling in a Sub Study
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\\xa0The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Depemokimab | Depemokimab will be administered. |
Timeline
- Start date
- 2025-07-11
- Primary completion
- 2027-12-08
- Completion
- 2028-02-11
- First posted
- 2025-05-18
- Last updated
- 2026-03-03
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06979323. Inclusion in this directory is not an endorsement.